Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain

Brain Structure and Function

Volumn 220, Issue 5, 2015, Pages 3043-3051

  Gulyás, Balázs ^a   Sovago, Judit ^b   Gomez Mancilla, Baltazar ^b   Jia, Zhisheng ^a   Szigeti, Csaba ^c   Gulya, Károly ^c   Schumacher, Martin ^b   Maguire, Ralph Paul ^b   Gasparini, Fabrizio ^b   Halldin, Christer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Autoradiography; Encephalin; Human brain; Huntington s disease; Immunohistochemistry; mGluR5; Substance P; 11C ABP688; 3H ABP688

Indexed keywords

ABP688 C11; ABP688 H 3; ENKEPHALIN; METABOTROPIC RECEPTOR 5; RADIOLIGAND; SUBSTANCE P; UNCLASSIFIED DRUG; GRM5 PROTEIN, RAT;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CAUDATE NUCLEUS; CELL COUNTING; CELL DENSITY; CEREBELLUM; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUNTINGTON CHOREA; IMMUNOREACTIVITY; ISOTOPE LABELING; MALE; MIDDLE AGED; POSTHUMOUS CARE; PRIORITY JOURNAL; PUTAMEN; RECEPTOR DENSITY; AUTOPSY; BRAIN; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY;

AGED; AUTOPSY; BRAIN; ENKEPHALINS; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, METABOTROPIC GLUTAMATE 5; SUBSTANCE P;

EID: 84940596157     PISSN: 18632653     EISSN: 18632661     Source Type: Journal    
DOI: 10.1007/s00429-014-0812-y     Document Type: Article

References (46)

1. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458
2. Airaksinen AJ, Nag S, Finnema SJ, Mukherjee J, Chattopadhyay S, Gulyás B, Farde L, Halldin C (2008) [11C]cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors. Bioorg Med Chem 16:6467–6473
3. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, Auberson YP, Gasparini F, Schubiger PA (2006) Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 47:698–705
4. Augood SJ, Faull RL, Love DR, Emson PC (1996) Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington’s disease: a detailed cellular in situ hybridization study. Neuroscience 72:1023–1036
5. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B. (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26:1243–1250
6. Canzoniero LMT, Granzotto A, Turetsky DM, Choi DW, Dugan LL, Sensi SL (2013) nNOS(+) striatal neurons, a subpopulation spared in Huntington’s disease, possess functional NMDA receptors but fail to generate mitochondrial ROS in response to an excitotoxic challenge. Front Physiol 16(4):112
7. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA 95:6480–6485
8. Cicchetti F, Prensa L, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease. Brain Res Brain Res Rev 34:80–101
9. Combs JW, Lagunoff D, Benditt EP (1965) Differentiation and proliferation of embryonic mast cells of the rat. J Cell Biol 25:577–592
10. Conn PJ, Battaglia G, Marino MJ, Nicoletti F (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6:787–798
11. Dawbarn D, Zamir N, Waters CM, Hunt SP, Emson PC, Brownstein MJ (1986) Peptides derived from prodynorphin are decreased in basal ganglia of Huntington’s disease brains. Brain Res 372:155–158
12. Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A (2004) Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study. J Chem Anat 27:143–164
13. Dutt MK (1980) Method for the demonstration of DNA-phosphate groups and DNA-aldehyde molecules with a basic dye, methylene green. Cell Mol Biol Incl Cyto Enzymol 26:159–163
14. Farkas S, Nagy K, Jia Z, Hortobágyi T, Varrone A, Halldin C, Csiba L, Gulyás B (2012) Signal transduction pathway activity compensates dopamine D(2)/D(3) receptor density changes in Parkinson’s disease: a preliminary comparative human brain receptor autoradiography study with [(3)H]raclopride and [(3)(5)S]GTPgammaS. Brain Res 1453:56–63
15. Feger J, Crossman AR (1984) Identification of different subpopulations of neostriatal neurones projecting to globus pallidus or substantia nigra in the monkey: a retrograde fluorescence double-labelling study. Neurosci Lett 49:7–12
16. Ferrante RJ, Kowall NW, Richardson EP Jr, Bird ED, Martin JB (1986) Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington’s disease striatum. Neurosci Lett 71:283–288
17. Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, Surmeier DJ, Honig MG, Carlock LR, Reiner A (1999) Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington’s disease. J Neurosci 19:1189–1202
18. Fuxe K, Marcellino D, Leo G, Agnati LF (2010) Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. Curr Opin Pharmacol 10:14–22
19. Galvan A, Wichmann T (2007) GABAergic circuits in the basal ganglia and movement disorders. Prog Brain Res 160:287–312
20. Gerfen CR, Young WS 3rd (1998) Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res 460:161–167
21. Gulyás B, Brockschnieder D, Nag S, Pavlova E, Kása P, Beliczai Z, Légrádi A, Gulya K, Thiele A, Dyrks T, Halldin C (2010) The norepinephrine transporter (NET) radioligand (S, S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer’s disease: a post-mortem autoradiographic study. Neurochem Int 56:789–798
22. Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, Keller E, Horváth MC, Nag S, Hermecz I, Magyar K, Halldin C (2011) Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography. Neurochem Intl 58:60–68
23. Hall H, Lundkvist C, Halldin C, Farde L, Pike VW, McCarron JA, Fletcher A, Cliffe IA, Barf T, Wikström H, Sedvall G (1997) Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res 745:96–108
24. Hall H, Halldin C, Farde L, Sedvall G (1998) Whole hemisphere autoradiography of the postmortem human brain. Nucl Med Biol 25:715–719
25. Heinsen H, Rub U, Bauer M, Ulmar G, Bethke B, Schüler M, Böcker F, Eisenmenger W, Götz M, Korr H, Schmitz C (1999) Nerve cell loss in the thalamic mediodorsal nucleus in Huntington’s disease. Acta Neuropathol 97:613–622
26. Hintermann S, Vranesic I, Allgeier H, Brülisauer A, Hoyer D, Lemaire M, Moenius T, Urwyler S, Whitebread S, Gasparini F, Auberson YP (2007) ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorg Med Chem 15:903–914
27. Macdonald V, Halliday G (2002) Pyramidal cell loss in motor cortices in Huntington’s disease. Neurobiol Dis 10:378–386
28. Marshall PE, Landis DM, Zalneraitis EL (1983) Immunocytochemical studies of substance P and leucine-enkephalin in Huntington’s disease. Brain Res 289:11–26
29. Mullen RJ, Buck CR, Smith AM (1992) NeuN, a neuronal specific nuclear protein in vertebrates. Development 116:201–211
30. Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, Richardson EP Jr, Bird ED (1991) Decreased neuronal and increased oligodendroglial densities in Huntington’s disease caudate nucleus. J Neuropathol Exp Neurol 50:729–742
31. Ouattara B, Gasparini F, Morissette M, Grégoire L, Samadi P, Gomez-Mancilla B, Di Paolo T (2010) Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem 113:715–724
32. Ouattara B, Gregoire L, Morissette M, Gasparini F, Vranesic I, Bilbe G, Johns DR, Rajput A, Hornykiewicz O, Rajput AH, Gomez-Mancilla B, Di Paolo T (2011) Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 32:1286–1295
33. Popoli P, Pezzola A, Torvinen M, Reggio R, Pintor A, Scarchilli L, Fuxe K, Ferré S (2001) The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 25:505–513
34. Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A, Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E (2010) Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy—implications for excitotoxicity. PLoS One 5(11):e14020
35. Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 85:5733–5737
36. Reiner A, Shelby E, Wang H, Demarch Z, Deng Y, Guley NH, Hogg V, Roxburgh R, Tippett LJ, Waldvogel HJ, Faull RL (2013) Striatal parvalbuminergic neurons are lost in Huntington’s disease: implications for dystonia. Mov Disord 28:1691–1699
37. Ribeiro FM, Paquet M, Ferreira LT, Cregan T, Swan P, Cregan SP, Ferguson SS (2010) Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington’s disease. J Neurosci 30:316–324
38. Sapp E, Ge P, Aizawa H, Bird E, Penney J, Young AB, Vonsattel JP, DiFiglia M (1995) Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington’s disease using high resolution image analysis. Neuroscience 64:397–404
39. Schiefer J, Sprünken A, Puls C, Lüesse HG, Milkereit A, Milkereit E, Johann V, Kosinski CM (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington’s disease. Brain Res 1019:246–254
40. Selemon LD, Goldman-Rakic PS (1990) Topographic intermingling of striatonigral and striatopallidal neurons in the rhesus monkey. J Comp Neurol 297:359–376
41. Senior W (1969) Staining of animal tissues with the dye base of methylene green in benzene to facilitate identification and selection of material. Stain Technol 44:269–271
42. Spargo E, Everall IP, Lantos PL (1993) Neuronal loss in the hippocampus in Huntington’s disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 56:487–491
43. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369–384
44. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577
45. Walker FO (2007) Huntington’s disease. Lancet 369:218–228
46. Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson’s disease and Huntington’s chorea. Neuroscience 25:419–438